cholesterol metabolisme hypercholesterolemia
Conditions
Interventions
During the entire study period, volunteers are instructed to consume a diet
according to the Dutch dietary guidelines (35 en% fat (10en% saturated fat),
50-55 en% carbohydrates). During the two week
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Subjects are asked to fill out a general health questionnaire in between the first and second screening visit. Only healthy subjects will be included. Obviously, the remark healthy only concerns the aspects checked for in the in and exclusion criteria. The inclusion criteria are: • aged between 18 and 70 years • fasting serum total cholesterol between 5.5 - 8.0 mmol/L • fasting plasma glucose
Exclusion criteria
Exclusion criteria: • unstable body weight (weight gain or loss >3 kg in the past 3 months) • allergic for eggs or egg-rich products • allergic or intolerant for cow-milk (lactose) based products • indication for treatment with cholesterol-lowering drugs according to the Dutch Cholesterol Consensus • use of medication or a diet known to affect serum lipid or glucose metabolism • active cardiovascular disease (for instance congestive heart failure) or recent (21 alcohol consumptions a week • women: consumption of >14 alcohol consumptions a week • abuse of drugs • pregnant or breastfeeding women • participation in another biomedical study within 1 month prior to the screening visit • having donated blood (as blood donor) within 1 month prior to the screening visit or planning to do so during the study • impossible or difficult venipuncture as evidenced during the screening visits
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measurements will be performed during the run-in period (days 0, 11 and 14) and during the experimental period (days 56, 95 and 98). The main effects (egg-yolk and buttermilk consumption) will be calculated as the absolute differences between values obtained at the end of the experimental (average days 95 and 98) and run-in (average days 11 and 14) periods. The primary endpoint is the change in serum LDL-cholesterol concentrations. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary endpoints are changes in serum total and HDL cholesterol, triacylglycerol, apoA-I, apoB and hsCRP concentrations. In addition, we would like to determine, via DNA analysis, polymorphisms in genes that play a role in (LDL) cholesterol metabolism, such as genes coding for the LDL receptor, PCSK9, SRBI, HMG-CoA reductase, ApoB and ApoE. | — |
Countries
Netherlands
Outcome results
None listed